BioCentury
ARTICLE | Clinical News

ISIS-APOCIIIRx: Phase III started

September 1, 2014 7:00 AM UTC

Isis began the double-blind, placebo-controlled, international Phase III APPROACH trial to evaluate 300 mg subcutaneous ISIS-APOCIIIRx once weekly for 26 weeks in about 50 patients with familial chylo...